News
New U.S. cancer cases may exceed 2.3 million by 2035
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report, detailing recent advances in the fight against...
News
AACR: New cancer cases predicted to rise above 2.3 million by 2035
The AACR annual Cancer Progress Report highlights 22 new approvals, including “revolutionary” CAR T-cell therapies, but maintains that increasing...
News
FDA grants full approval to pembrolizumab for advanced NSCLC
The checkpoint inhibitor is approved with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC, with no...
News
FDA grants accelerated approval for Opdivo in metastatic SCLC
The checkpoint inhibitor is approved for patients with advanced SCLC whose cancer has progressed after platinum-based chemotherapy and at least...
News
FDA requires companion diagnostics for checkpoint inhibitors in urothelial cancer
PI now requires separate companion diagnostics to determine PD-L1 levels in tumor tissue before use of pembrolizumab or atezolizumab as...
News
FDA approves lenvatinib for HCC
Lenvatinib was found noninferior but not statistically superior to sorafenib for overall survival in a trial of 954 patients.
News
Phase 1 CAR T trial for NHL launches in Cleveland
The trial will enroll 12-15 adult patients with non-Hodgkin lymphoma who have not responded to standard therapies.
News
ASCO calls for expanding clinical trial eligibility
ASCO and Friends of Cancer Research submitted recommendations for expanding clinical trial eligibility to the FDA, including lowering eligibility...
News
FDA expands indication for ribociclib for advanced breast cancer
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in...
News
FDA approves first biosimilar to pegfilgrastim
The biosimilar decreases the chance of infection in patients with nonmyeloid cancer who are at risk of febrile neutropenia because of...
Video
Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2018
CHICAGO – TAILORx is a “big win,” while SANDPIPER results are nothing to get excited about.
News
New cases of Merkel cell carcinoma increased 95% between 2000 and 2013
Incidence expected to be over 3,000 cases/year in United States by 2025.
News
Company discontinues phase 3 ADAPT for mRCC
A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to...
News
FDA approves osimertinib for first-line advanced EGFR-mutated NSCLC
Approval was based on a median PFS of 18.9 months for patients treated with osimertinib vs. 10.2 months for patients treated with standard-of-care...
News
FDA approves immunotherapy combo for advanced RCC
Approvals were granted for nivolumab and ipilimumab in combination for the treatment of intermediate- or poor-risk, previously untreated advanced...